NASDAQ:JBIO
Jade Biosciences, Inc.
Jade Biosciences, Inc. reported net income of −$127.4M in fiscal 2025. Free cash flow was −$94.9M, and the diluted share count rose 9.7%.Summary generated from Jade Biosciences, Inc.'s SEC filings. Latest annual report filed Mar 6, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−89.2%
Debt / equityn/a
Free cash flow−$94.9M
FCF marginn/a
Share count change+9.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −23 | −53 | −81 | −75 | −114 |
| Net income | −23 | −52 | −76 | −70 | −127 |
| Free cash flow | −28 | −39 | −57 | n/a | −95 |
Recent filings
- 8-KOther events
Sep 30, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 8-KResults of operations and financial condition
Aug 10, 2026 - 8-KEntry into a material agreement
Jul 1, 2026 - 4Insider transaction report
Jun 26, 2026 - 8-KDirector or officer change
Jun 26, 2026 - 4Insider transaction report
Jun 11, 2026 - 8-KAmendment to articles or bylaws
Jun 11, 2026